1 Redefining Cancer Care

2

Disclaimer

This presentation may include predictions, estimates or other information that might be considered forward-looking. While these forward looking statements represent COTI’s current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. COTI has based any forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents COTI has filed with the Toronto Stock Exchange and Ontario Securities Commission. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinion only as of the date of this presentation.

Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of any new information or future events.

3

~ $35B personalized cancer gene profiling market by 2018*

* Markets and Markets (2013) 3

4

Big data problem

How to use information from cancer gene profiling to truly personalize therapy

4

5

Billions

540,000+

1 size

Too many combinations to evaluate?

of mutation profiles

unique single, double & triple drug combos from just 150 drugs

does not fit all!

5

6

Our solution…

Uses gene profile of patient’s tumor to evaluate full range of available therapies

Programmable computer simulation of a human cancer cell

R O S A L I N D R O S A L I N D

7

~100 core processors

10,878* simulations

Results in < 2 hours

* All possible single drugs and 2 drug combinations for 147 drugs

Advantages of ROSALIND

Comprehensiveness and speed

8

Advantages of ROSALIND

Safety: Simulate rather than experiment

Efficiency: Assign patients to most appropriate therapy or clinical trial when predicted optimal therapies are not yet available

9

Our vision

More personalized cancer treatments Higher remission rates + lower cost of cancer therapy

10

Potential revenue models

Patient-based model

Software as a Service

Online service: web portal

11

Patient-based model

0.1% market: $1.6 million

1% market: $16.4 million

5% market: $81.9 million

10% market: $163.9 million

Assumptions: Analysis ordered by attending MD Cost ~$1,000 per patient ~1.6 million new cases annually in US

12

Bronze

Silver

Gold

Platinum

Annual licensing fee

$25,000

$75,000

$150,000

$500,000

Limited users

Limited cases

Medium-sized users

More cases

More users

More features

More cases

Unlimited users

Full features

Unlimited cases

Software as a Service model (SaaS)

13

Online service: web portal

Serves largest population at lowest cost with fastest turn-around and highest security:

– Independently, either in the cloud or on secure servers, and/or

– A version can be offered through an existing online provider (COTI, Google, etc.)

– iTunes type of customizable billing depending on number of drugs/combinations to be evaluated

14

ROSALIND adopted by medical community; demanded by patients

ROSALIND accepted, reimbursed, and ultimately required, by healthcare insurers and payers

Realistic goals

15

Validation – next steps

Database (ROSALIND): 1 patient = 1 gene profile

Obtain patient biopsy at time of diagnosis

Genetic profiling and xenograft (1 xenograft = 1 patient)

Use ROSALIND to predict optimal therapies for genetic profile in question

Use top 2 or 3 predictions for xenograft confirmation

Add to database for future reference

Grow database with global results and translate into personalized treatment options

Phase 1: perhaps 1,000 patients/gene profiles

16

Actual human tumor gene profile

Mutations:

• Oncogenes: EGFR, CCND1

• Tumor suppressor: ARID1A

Example: Actual Commercial Profile

Some common therapies for this profile could include:

Gefitinib

Carboplatin

Paclitaxel (Abraxane)

Gemcitabine

Irinotecan

17

Actual Patient Profile (cont’d)

ROSALIND evaluated just 129 options:

Remission is not possible with any single drug

BUT - remission may be possible with:

Gefitinib or Tarceva or Cetuximab or Panitumumab + Paclitaxel or

Carboplatin + Paclitaxel or

Gemcitabine + Paclitaxel or

Irinotecan + Paclitaxel

There are also several other Paclitaxel based 3 drug combinations that could be considered

18

Thank you

For more information, please contact:

Dr. Wayne R. Danter, President & CEO

Critical Outcome Technologies, Inc. Suite 213, 700 Collip Circle, London, Ontario, Canada N6G 4X8

T: (519) 858-5157 E: wdanter@criticaloutcome.com